Chronic myelomonocytic leukemia: JAK2 inhibitor ruxolitinib has promising efficacy
Scientists are reporting on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients.
Scientists are reporting on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients.
SOURCE: Top Health News — ScienceDaily – Read entire story here.